KBC Group’s Summit Therapeutics SMMT Stock Holding History

KBC Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$111K	Buy	+6,566	New	+$98.2K	﹤0.01%	1318

Other funds holding SMMT

Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

Blankinship & Foster Solana Beach, California $490M AUM 14.37% 1-Year Est. Return

KBC Group's SMMT Position: Q3 2026 in Review

KBC Group opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 6,566 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #1318 among its holdings.

32 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

KBC Group held 6,566 shares of Summit Therapeutics worth $111K as of Q3 2026.
Summit Therapeutics was a new KBC Group position in Q3 2026.
Summit Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1318 holding.
32 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.